U.S. markets closed

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2787+0.0017 (+0.61%)
At close: 3:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2770
BidN/A x N/A
AskN/A x N/A
Day's Range0.2700 - 0.3000
52 Week Range0.1990 - 2.2000
Avg. Volume657,203
Market Cap66.522M
Beta (5Y Monthly)4.50
PE Ratio (TTM)N/A
EPS (TTM)-0.1510
Earnings DateMay 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MYCOF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Lions Gate Entertainment Corp.Lionsgate produces and distributes motion pictures and television shows globally through theatrical, television, home video, and digital platforms. It acquired Summit Entertainment, another small studio, in January 2012 and the Starz premium cable channel in December 2016. A primary focus for the company is the young adult audience. It has two mega-grossing franchises in 'The Hunger Games' and 'The Twilight Saga,' as well as a number of lower-profile genre-oriented titles targeted at the horror, urban, and Hispanic markets. The company generated 18% of its FY18 revenue outside the U.S. With the Starz merger, Lionsgate created two new share classes to replace its old share classes. The new Lionsgate Series A voting shares are denominated LGF.A by the company, LGF/A by Bloomberg, and LGF-A by Yahoo Finance. The Series B nonvoting shares are likewise denominated LGF.B by the company, LGF/B by Bloomberg, and LGF-B by Yahoo Finance. There are 83 million Series A shares outstanding, and the LGF/A ticker retains the historical and volume trading data. There are 137.5 million Series B shares outstanding. Investors should note that Argus covers the ticker LGF/A, and therefore the market capitalization on the Argus website reflects only LGF/A and not the combined LGF/A and LGF/B shares.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • CNW Group

    KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

    Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.

  • PR Newswire

    Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th

    Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that Josh Bartch, CEO of Mydecine, will participate in the KCSA Psychedelics Investor Conference to be held at on October 13-14, 2021.

  • GlobeNewswire

    Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

    Research to take place at Johns Hopkins, New York University and University of Alabama BirminghamDENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being conducted at Johns Hopkins University (“JHU”), Ne